NervGen released expanded CONNECT SCI data showing durable functional improvements and quality‑of‑life gains in individuals with chronic spinal cord injury treated with NVG‑291. The company reported sustained benefits at week 16 and in blinded exit interviews up to 364 days, including patient‑reported improvements in bladder control and spasticity. NervGen said neurophysiologic measures (MEP, startle MEP) link the clinical effects to changes in corticospinal and reticulospinal signaling, and that FDA confirmed multiple regulatory paths are available for NVG‑291. The dataset bolsters NervGen’s regulatory discussions and underpins claims of a potential first pharmacologic therapy for SCI repair.